A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers
Latest Information Update: 22 Nov 2021
At a glance
- Drugs Dinalbuphine-sebacate (Primary) ; Nalbuphine
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Lumosa Therapeutics
- 11 Nov 2021 Status changed from recruiting to completed.
- 31 Aug 2020 Planned End Date changed from 31 Jul 2020 to 31 Dec 2020.
- 03 Feb 2020 Status changed from planning to recruiting.